{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:23Z","timestamp":1791252803094,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.semnuclmed.2011.02.003","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T14:51:42Z","timestamp":1308840702000},"page":"246-264","source":"Crossref","is-referenced-by-count":95,"title":["A Broad Overview of Positron Emission Tomography Radiopharmaceuticals and Clinical Applications: What Is New?"],"prefix":"10.1053","volume":"41","author":[{"given":"Shankar","family":"Vallabhajosula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Vallabhajosula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2011.02.003_bib1","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/jo00433a037","article-title":"Fluorination with F2: convenient synthesis of 2-deoxy-2-fluoro-d-glucose","volume":"42","author":"Ido","year":"1977","journal-title":"J Org Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib2","article-title":"Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution","volume":"27","author":"Hamacher","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0969-8043(95)00258-8","article-title":"Basic previous term hydrolysis next term 2-[18F]fluoro-1,3,4,6-tetra-O-acetyl-image-glucose in the preparation of 2-[18F]fluoro-2-deoxy-Image-glucose","volume":"47","author":"F\u00fcchtner","year":"1996","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib4","first-page":"36","article-title":"Radioisotope products and their availability","year":"2010","journal-title":"Nuclear Technology Review"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semnuclmed.2007.08.004","article-title":"18F-Labelled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanism of tumor localization","volume":"37","author":"Vallabhasojula","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib6","series-title":"Molecular Imaging: Radiopharmaceuticals for PET and SPECT","year":"2009"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.003_bib7","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.2967\/jnumed.108.057281","article-title":"Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET","volume":"50","author":"Dunphy","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.nucmedbio.2010.04.185","article-title":"Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences","volume":"37","author":"Coenen","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ejrad.2009.12.022","article-title":"Basics and principles of radiopharmaceuticals for PET\/CT","volume":"73","author":"Wadsak","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00259-009-1301-z","article-title":"Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease","volume":"37","author":"N\u00e5gren","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib11","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: a PET agent for amyloid beta plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s00259-009-1357-9","article-title":"Recent advances in PET imaging for evaluation of Parkinson's disease","volume":"37","author":"Sioka","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrcardio.2009.119","article-title":"Molecular imaging in cardiovascular disease: targets and opportunities","volume":"6","author":"Shaw","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib14","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehq361","article-title":"Assessment of myocardial ischaemia and viability: role of positron emission tomography","volume":"31","author":"Ghosh","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib15","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.2967\/jnumed.109.068122","article-title":"Multimodality cardiovascular molecular imaging: an overview","volume":"51","author":"Sinusas","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2967\/jnmt.107.044156","article-title":"Procedure guideline for the use of radiopharmaceuticals 4.0","volume":"35","author":"Callahan","year":"2007","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib17","first-page":"12999","article-title":"products, safety and effectiveness of certain PET drugs for specific indications","volume":"65","year":"2000","journal-title":"Fed Regist"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib18","first-page":"13010","article-title":"FDG F-18 injection, ammonia N 13 injection, and sodium fluoride F-18 injection","volume":"65","year":"2000","journal-title":"Fed Regist"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib19","first-page":"65409","article-title":"Current good manufacturing practice (CGMP) for positron emission tomography drug products","volume":"74","year":"2009","journal-title":"Fed Regist"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib20","first-page":"65538","article-title":"current good manufacturing practice","volume":"74","year":"2009","journal-title":"Fed Regist"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.semnuclmed.2010.05.002","article-title":"Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals","volume":"40","author":"Harapanhalli","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","author":"Park","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-540-49527-7_8","article-title":"68Ga-PET radiopharmacy: a generator-based alternative to 18F radiopharmacy","volume":"62","author":"Maecke","year":"2007","journal-title":"Ernst Schering Res Found Workshop"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.107.040378","article-title":"Processing of generator-produced 68 Ga for medical application","volume":"48","author":"Zhernosekov","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s00259-007-0387-4","article-title":"The 68 Ge\/68Ga generator has high potential, but when can we use 68 Ga-labelled tracers in clinical routine?","volume":"34","author":"Breeman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib26","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-005-1906-9","article-title":"A comparison of PET imaging characteristics of various copper radioisotopes","volume":"32","author":"Williams","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","article-title":"Standardized methods for the production of high specific-activity zirconium-89","volume":"36","author":"Holland","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2967\/jnumed.108.056887","article-title":"Antibodies and antimatter: the resurgence of immuno-PET","volume":"50","author":"Wu","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.semnuclmed.2011.02.002","article-title":"The next generation of PET radiopharmaceuticals in oncology","volume":"41","author":"Rice","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.semnuclmed.2011.02.001","article-title":"68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for PET","volume":"41","author":"Breeman","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.semnuclmed.2011.02.005","article-title":"PET radiopharmaceuticals for imaging brain beta amyloid (A\u03b2)","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.semnuclmed.2011.03.001","article-title":"Florbetapir F-18: a histopathologically-validated \u03b2-amyloid PET imaging agent","volume":"41","author":"Lister-James","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.semnuclmed.2011.02.004","article-title":"The next generation of cardiac PET imaging agent: discovery of Flurpiridaz F 18 for detection of coronary disease","volume":"41","author":"Yu","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.semnuclmed.2010.03.006","article-title":"The Clinical Trials Network of the Society of Nuclear Medicine","volume":"40","author":"Graham","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib35","first-page":"332","article-title":"A new isotope for bone scanning","volume":"3","author":"Blau","year":"1962","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/snuc.2001.18742","article-title":"Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate","volume":"31","author":"Blake","year":"2001","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2007.07.002","article-title":"18F-fluoride positron emission tomography and positron emission tomography\/computed tomography","volume":"37","author":"Even-Sapir","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18F-fluoride: applying new technology to an old tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib39","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2967\/jnumed.110.082263","article-title":"SNM practice guideline for sodium 18 F-fluoride PET\/CT bone scans 1.0","volume":"51","author":"Segall","year":"2010","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.003_bib40","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/s00259-007-0697-6","article-title":"Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies","volume":"35","author":"Drzezga","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000256373.39415.b1","article-title":"Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis","volume":"68","author":"Forman","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.nucmedbio.2007.06.015","article-title":"Impact of amyloid imaging on drug development in Alzheimer's disease","volume":"34","author":"Mathis","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wad.0000191420.61260.a8","article-title":"The role of biomarkers in clinical trials for Alzheimer disease and associated disorders","volume":"20","author":"Thal","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib44","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2004.08.004","article-title":"Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease","volume":"1025","author":"Kung","year":"2004","journal-title":"Brain Res"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib47","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1021\/jm050166g","article-title":"F-18 stilbenes as PET imaging agents for detecting \u03b2-amyloid plaques in the brain","volume":"48","author":"Zhang","year":"2005","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib48","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: a PET agent for A\u03b2 plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging \u03b2-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib50","unstructured":"Kolata G: F.D.A. Sees Promise in Alzheimer's Imaging Drug, The New York Times, January 20, 2011"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid \u03b2 in Alzheimer's disease with 1F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib52","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2967\/jnumed.108.060756","article-title":"Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging","volume":"50","author":"Koole","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib53","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18 F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/WCO.0b013e3283168e1a","article-title":"The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation","volume":"21","author":"Klunk","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0969-8051(97)00101-7","article-title":"In vivo radiotracers for vesicular neurotransmitter transporters","volume":"24","author":"Kilbourn","year":"1997","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib57","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.410400609","article-title":"Presynaptic monoaminergic vesicles in Parkinsons's disease and normal aging","volume":"40","author":"Frey","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.nucmedbio.2006.12.005","article-title":"Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters","volume":"34","author":"Kung","year":"2007","journal-title":"Nucl Med Biol"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib59","first-page":"31N","article-title":"SNM highlights lecture: neuroscience","volume":"51","author":"Rowe","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.108.051680","article-title":"In vivo imaging of beta-cell mass in rats using 18 F\u2013FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus","volume":"49","author":"Kung","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00109-007-0242-x","article-title":"VMAT2 gene expression and function as it applies to imaging beta-cell mass","volume":"86","author":"Harris","year":"2008","journal-title":"J Mol Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib62","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s00259-007-0648-2","article-title":"Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates","volume":"35","author":"Murthy","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib63","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2967\/jnumed.110.078196","article-title":"Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent","volume":"51","author":"Lin","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2967\/jnumed.108.054866","article-title":"11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls","volume":"50","author":"Goland","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2967\/jnumed.109.074492","article-title":"Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat and human pancreas","volume":"51","author":"Mikkola","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib66","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehq361","article-title":"Assessment of myocardial ischaemia and viability: role of positron emission tomography","volume":"31","author":"Ghosh","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib67","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.108.054478","article-title":"The clinical value of myocardial blood flow measurement","volume":"50","author":"Camici","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1536-1632(02)00116-6","article-title":"From thallium scan to molecular imaging","volume":"4","author":"Schwaiger","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.semnuclmed.2006.08.002","article-title":"Comparative use of radionuclide stress testing, coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and prognostic cardiac assessment","volume":"37","author":"Berman","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib70","article-title":"Positron emission tomography of the heart: methodology, findings in the normal and disease heart, and clinical applications, in Phelps ME (ed): PET: Molecular Imaging and Its Clinical Applications","author":"Schelbert","year":"2004","journal-title":"New York, Springer"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib71","first-page":"201","article-title":"Quantification of myocardial perfusion in human subjects using 82 Rb and wavelet-based noise reduction","volume":"42","author":"Lin","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib72","first-page":"272","article-title":"Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer: comparison with 99mTc-sestamibi","volume":"42","author":"Marshall","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib73","first-page":"1359","article-title":"Characterization of uptake of the new PET imaging compound 18 F-fluorobenzyl triphenyl phosphonium in dog myocardium","volume":"47","author":"Madar","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib74","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.nuclcard.2007.07.009","article-title":"Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent","volume":"14","author":"Yalamanchili","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib75","first-page":"II-761","article-title":"[18F]-RP1012: a novel myocardial perfusion imaging agent for use with positron emission tomography (PET)","volume":"112","author":"Yu","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.nuclcard.2007.07.008","article-title":"BMS-747158-02: a novel PET myocardial perfusion imaging agent","volume":"14","author":"Yu","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib77","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2967\/jnumed.107.044727","article-title":"Initial characterization of an 18F-labeled myocardial perfusion tracer","volume":"49","author":"Huisman","year":"2008","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib78","first-page":"15N","article-title":"SNM highlights lecture: cardiovascular disease","volume":"51","author":"Schwaiger","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib79","first-page":"331","article-title":"Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumors","volume":"40","author":"Shoup","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib80","first-page":"56","article-title":"Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma","volume":"48","author":"Schuster","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib81","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2967\/jnumed.106.037689","article-title":"Clinical applications of PET in brain tumors","volume":"48","author":"Chen","year":"2007","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib82","first-page":"19N","article-title":"SNM highlights lecture: oncology","volume":"51","author":"Larson","year":"2010","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib83","first-page":"456","article-title":"Report of a clinical trial of anti-1 amino 3 [18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) PET-CT in recurrent prostate carcinoma","volume":"51","author":"Schuster","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/jm101068q","article-title":"4-[18F]Fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization","volume":"54","author":"Krasikova","year":"2011","journal-title":"J Med Chem"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib85","first-page":"118","article-title":"[18F]BAY 85-8050 (TIM-1): a novel tumor specific probe for PET\/CT imaging\u2014first clinical results","volume":"51","author":"Krause","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1389450033346830","article-title":"Integrin \u03b1V\u03b23 as a therapeutic target for blocking tumor-induced angiogenesis","volume":"4","author":"Kumar","year":"2003","journal-title":"Curr Drug Targets"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib87","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.270.5241.1500","article-title":"Definition of two angiogenic pathways by distinct \u03b1V integrins","volume":"270","author":"Friedlander","year":"1995","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib88","first-page":"1061","article-title":"Radiolabeled \u03b1V\u03b23 integrin antagonists: a new class of tracers for tumor targeting","volume":"40","author":"Haubner","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib89","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1371\/journal.pmed.0020070","article-title":"Noninvasive visualization of the activated alpha v beta3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD","volume":"2","author":"Haubner","year":"2005","journal-title":"PLoS Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib90","first-page":"1552","article-title":"Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates","volume":"46","author":"Line","year":"2005","journal-title":"J NuclMed"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib91","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.107.049452","article-title":"Phase I trial of the positron-emitting ArgGlyAsp (RGD) peptide radioligand 18 F-AH111585 in breast cancer patients","volume":"49","author":"Kenny","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib92","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1016\/j.bmcl.2006.09.033","article-title":"NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging","volume":"16","author":"Indrevoll","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib93","first-page":"505","article-title":"A novel PET imaging approach for detection of tumor angiogenesis via the expression of v\u03b23 integrin using an RGD peptide, [18F]fluciclatide (AH111585)","volume":"51","author":"Mena","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semnuclmed.2010.09.003","article-title":"Molecular imaging of the kidneys","volume":"41","author":"Szabo","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib95","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(07)70044-X","article-title":"Preoperative characterization of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial","volume":"8","author":"Divgi","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib96","first-page":"43","article-title":"Thymidine metabolism and cell kinetics","volume":"6","author":"Cleaver","year":"1967","journal-title":"Front Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib97","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1073\/pnas.69.4.988","article-title":"Detection of DNA synthesis in intact organisms with positron-emitting methyl-[C-11]-thymidine","volume":"69","author":"Christman","year":"1972","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib98","first-page":"1432","article-title":"PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls","volume":"44","author":"Shields","year":"2003","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib99","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.2967\/jnumed.107.046391","article-title":"Imaging of cell proliferation: status and prospects","volume":"49","author":"Bading","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.semnuclmed.2007.08.001","article-title":"FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3\u2032-deoxy-3\u2032-[18F]fluorothymidine","volume":"37","author":"Salskov","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nucmedbio.2007.09.003","article-title":"In vivo measurement of cell proliferation in canine brain tumor using C-11 labeled FMAU and PET","volume":"35","author":"Conti","year":"2008","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00259-004-1713-8","article-title":"Imaging DNA synthesis in vivo with [F-18]FMAU and positron emission tomography in patients with cancer","volume":"32","author":"Sun","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib103","doi-asserted-by":"crossref","first-page":"129S","DOI":"10.2967\/jnumed.107.045914","article-title":"Molecular imaging of hypoxia","volume":"49","author":"Krohn","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.mibio.2004.06.007","article-title":"Functional Imaging of intra-tumoral hypoxia","volume":"6","author":"Foo","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2307\/3576986","article-title":"Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells","volume":"111","author":"Rasey","year":"1987","journal-title":"Radiat Res"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib106","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1007\/s00259-009-1195-9","article-title":"Molecular imaging of hypoxia with radiolabelled agents","volume":"36","author":"Mees","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.semnuclmed.2007.07.001","article-title":"Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole","volume":"37","author":"Lee","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib108","first-page":"1155","article-title":"Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib109","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm0104217","article-title":"Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals","volume":"45","author":"Maurer","year":"2002","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib110","first-page":"177","article-title":"Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model","volume":"40","author":"Lewis","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib111","first-page":"183","article-title":"PET imaging of hypoxia","volume":"45","author":"Lewis","year":"2001","journal-title":"Q J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib112","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0960-0760(92)90184-K","article-title":"Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication","volume":"43","author":"Reubi","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.003_bib114","first-page":"67S","article-title":"Candidates for peptide receptor radiotherapy today and in the future","volume":"46","author":"Reubi","year":"2005","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.003_bib115","first-page":"172S","article-title":"68Ga-labeled peptides in tumor imaging","volume":"46","author":"Maecke","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib116","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","article-title":"Imaging of neuroendocrine tumors","volume":"36","author":"Rufini","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib117","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"2007","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib118","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","article-title":"Detection of unknown primary neuroendocrine tumors CUP-NET using 68Ga-DOTA-NOC receptor PET\/CT","volume":"37","author":"Prasad","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib119","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumor imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","author":"Virgolini","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.003_bib120","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1007\/s00259-005-1960-3","article-title":"Human gene therapy and imaging in neurological diseases","volume":"32","author":"Jacobs","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib121","first-page":"1851","article-title":"Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O","volume":"45","author":"Bruehlmeier","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.003_bib122","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:52:05Z","timestamp":1560300725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299811000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0001299811000328"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.02.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13272008.14628102","asserted-by":"object"}]},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}